Correlation Between Genmab AS and LUXOR-B

Can any of the company-specific risk be diversified away by investing in both Genmab AS and LUXOR-B at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Genmab AS and LUXOR-B into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Genmab AS and Investeringsselskabet Luxor AS, you can compare the effects of market volatilities on Genmab AS and LUXOR-B and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Genmab AS with a short position of LUXOR-B. Check out your portfolio center. Please also check ongoing floating volatility patterns of Genmab AS and LUXOR-B.

Diversification Opportunities for Genmab AS and LUXOR-B

-0.38

Correlation Coefficient

Genmab AS  LUXOR-B

Very good diversification

The 3 months correlation between Genmab and LUXOR-B is -0.38. Overlapping area represents the amount of risk that can be diversified away by holding Genmab AS and Investeringsselskabet Luxor AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Investeringsselskabet and Genmab AS is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Genmab AS are associated (or correlated) with LUXOR-B. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Investeringsselskabet has no effect on the direction of Genmab AS i.e., Genmab AS and LUXOR-B go up and down completely randomly.

Pair Corralation between Genmab AS and LUXOR-B

Assuming the 90 days trading horizon Genmab AS is expected to under-perform the LUXOR-B. But the stock apears to be less risky and, when comparing its historical volatility, Genmab AS is 1.42 times less risky than LUXOR-B. The stock trades about -0.18 of its potential returns per unit of risk. The Investeringsselskabet Luxor AS is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  54,000  in Investeringsselskabet Luxor AS on September 4, 2024 and sell it today you would earn a total of  1,500  from holding Investeringsselskabet Luxor AS or generate 2.78% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	98.46%
Values	Daily Returns

Genmab AS  vs.  Investeringsselskabet Luxor AS

Genmab AS

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Genmab AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Investeringsselskabet

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Investeringsselskabet Luxor AS are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, LUXOR-B is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Genmab AS and LUXOR-B

The main advantage of trading using opposite Genmab AS and LUXOR-B positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Genmab AS position performs unexpectedly, LUXOR-B can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in LUXOR-B will offset losses from the drop in LUXOR-B's long position.

The idea behind Genmab AS and Investeringsselskabet Luxor AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..